Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast Aim: To analyse the clinicopathological features and immunohistochemical characteristics of nine cases of salivary duct carcinoma (SDC) with rhabdoid features (SDCRF), representing a new, extremely rare type of salivary gland malignancy. Methods and results: We analysed 2511 cases of salivary gland tumour, clinicopathologically and immunohistochemically. The incidence of SDCRF was 0.4%. Eight patients were male. The age of patients ranged from 36 years to 85 years (mean, 61 years). SDC arose from the parotid glands and submandibular gland in six and three cases, respectively. Seven cases appeared as a carcinoma component of carcinoma ex pleomorphic adenoma cases. Six patients died of disease. Histologically, diffuse proliferations of non-coherent large ovoid or polygonal carcinoma cells with eosinophilic cytoplasm and eccentric nuclei were observed in all cases; such cytological characteristics were defined as 'rhabdoid features'. Immunohistochemically, all cases were positive for cytokeratin, gross cystic disease fluid protein-15, androgen receptor, and SMARCB1, seven cases were positive for HER2, and two cases were positive for epidermal growth factor receptor. However, all cases were negative for vimentin and myoepithelial markers. Eight cases showed no or aberrant expression of E-cadherin and b-catenin. The results suggest that SDCRF is an extremely rare subtype of SDC, and not a sarcomatoid variant of SDC. SDCRF is histologically unique, and is positive for SDC markers but negative for vimentin, unlike rhabdoid-type carcinomas arising from other organs. Conclusions: The morphogenesis of SDCRF is related to no or aberrant expression of cell-cell adhesion molecules. Therefore, SDCRF could be a salivary counterpart to pleomorphic lobular breast carcinoma.
Introduction
Salivary duct carcinoma (SDC) is a relatively common malignancy of the salivary glands, and is frequently observed in the carcinomatous component of carcinoma ex pleomorphic adenoma (CXPA).
1-3 SDC encompasses some histological variants such as sarcomatoid, [4] [5] [6] invasive micropapillary, 7 mucin-rich [8] [9] [10] and low-grade variants. [11] [12] [13] However, low-grade SDC was recently re-categorized as low-grade cribriform cystadenocarcinoma.
14 Pure salivary duct carcinoma in situ was also recently reported. 15 Only one case of sarcomatoid SDC has been reported to be composed of rhabdoid cells. 5 We recently reported two cases of SDC with rhabdoid features (SDCRF). 16 This subtype is extremely rare, and has unique histological features. Unlike the first description of sarcomatoid SDC, our two cases were positive for epithelial markers such as cytokeratin (CK), but negative for vimentin. Therefore, we speculate that this is not a subtype of sarcomatoid SDC. Accordingly, we examined the clinicopathological and immunohistochemical characteristics of two previously reported cases and seven additional cases.
Materials and methods
We retrospectively reviewed 2511 cases of surgically resected primary salivary gland tumour from the pathology files of our institutions from 1995 to 2014. We found 101 cases that showed histological features fulfilling the criteria for SDC according to the 2005 World Health Organization classification of salivary gland tumours; these cases also contained CXPA cases. Among these 101 SDCs, nine contained rhabdoid features. Clinical details and follow-up data were obtained from medical records, referring pathologists, and treating physicians.
Several tissue sections were fixed in 10% formalin, and processed and stained by the use of routine histological techniques, including Elastica van Gieson staining. Sections from formalin-fixed paraffin blocks of the primary and metastatic tumours were available for immunohistochemical staining in all cases. Immunohistochemical studies were performed with both the Autostainer (DakoCytomation, Carpinteria, CA, USA) and EnVision (DakoCytomation) automated immunohistochemical systems. The primary antibodies used are listed in Table 1 . Briefly, 3-lm sections were deparaffinized and hydrated with graded ethanol and water. Antigen retrieval was subsequently performed. Immunohistochemical analysis was performed with the EnVision system. The immunoreaction was visualized with the chromogen 3,3 0 -diaminobenzidine. The immunohistochemical results were evaluated by two independent observers (K.K. and T.N.), who determined the percentage of positive neoplastic cells. The tumours were considered to be diffusely positive (+++), positive (++), partially positive (+) and focally positive (F+) when there were ≥50%, 20-49%, 10-19% and 1-9% positive neoplastic cells, respectively. The HER2 score was estimated according to the criteria of Wolff et al. 17 Epidermal growth factor receptor (EGFR) expression was categorized as positive or negative. A case was considered to be p53-positive if >50% of the tumour cell nuclei showed strong reactivity, which is indicative of a p53 point mutation.
Carcinoma cells showing no p53 immunostaining despite weak positivity in the infiltrating lymphocytes raised high suspicion of deletion (i.e. loss) of p53. Weak p53 immunostaining was considered to be indicative of the presence of wild-type p53. The percentage of Ki67-positive cells was determined by counting the number of positively stained nuclei in least 1000 tumour cells; this was recorded as the Ki67 labelling index. For cases with an HER2 score of 2+, fluorescence in-situ hybridization (FISH) was performed with the PathVysion HER-2 DNA probe kit from Vysis (Abbott Molecular, Des Plasines, IL, USA), according to the manufacturer's instructions. Enumeration of the number of locus-specific identifier HER2 and chromosome 17 centromere signals per nucleus for 25 tumour cells was performed by two independent readers (K.K.and T.K.). A specimen was considered to be amplified for HER2 when the ratio was ≥2.0, and non-amplified when the ratio was <2.0.
Results
The incidence rates of SDCRF were 0.4% among all salivary gland tumours and 9% among all SDCs in our records. The clinicopathological features of SDCRF in the salivary glands are summarized in Table 2 .
Eight of the nine patients with SDCRF were men. The mean patient age was 61 years (range, 36-85 years). All cases presented with palpable masses or swelling. Six and three cases were from the parotid and submandibular glands, respectively. Five of the six parotid gland tumours showed tumour-related facial nerve palsy. Seven patients underwent total lobectomy or tumour excision, whereas one (case 9) only underwent neck dissection at our hospital. Case 2, which we reported previously, 15 was clinically diagnosed as metastatic carcinoma of unknown origin; however, the primary site was ultimately determined to be the submandibular gland. Seven patients underwent neck dissection, owing to multiple cervical lymph node metastases. One patient (case 5) only underwent open biopsy. Three patients received postoperative radiotherapy, and another three received postoperative chemoradiotherapy. Six patients died of disease. Two patients were alive without disease, whereas the other was lost to follow-up. Case 5 presented with multiple cervical lymph node metastases and lung metastases at the first consultation, whereas case 9 underwent submandibulectomy at a local hospital before being admitted to our hospital for the treatment of multiple cervical lymph node metastases. Eight cases showed multiple cervical lymph node metastases. None of the patients received antiandrogen therapy or trastuzumab (Herceptin) therapy. a-SMA, a-smooth muscle actin; AR, androgen receptor; CB, citrate buffer (pH 6.0); CK, cytokeratin; EGFR, epidermal growth factor receptor; EMA, epithelial membrane antigen; GCDFP-15, gross cystic disease fluid protein-15; MMG, mammaglobin; ND, not done; P/M, polyclonal/monoclonal; PSA, prostate-specific antigen; PTEN, phosphatase and tensin homologue located on chromosome 10; Proteinase, proteinase type XXIV (Sigma: 9014-01-1 in Tris buffer, pH 6.0, at room temperature for 5 min, water bath, incubate at 95°C for 45 min, autoclave, incubate at 121°C for 10 min); TE, Tris-EDTA buffer (pH 9.0).
P A T H O L O G I C A L F I N D I N G S
On gross examination, six cases showed an infiltrative growth pattern with elastic-hard round nodules on the cut surface ( Figure 1 ), whereas one case (case 6) showed a well-circumscribed and encapsulated mass. Five cases had yellowish to white round masses within the main tumours, whereas case 2 showed cystic change with a yellowish round nodule. Histologically, seven cases showed invasion into the adjacent salivary gland parenchyma, and frequently the fatty and muscular tissues. In seven cases, the tumours were accompanied by a benign pleomorphic adenoma (PA) component, whereas only one case (case 8) showed no evidence of PA tissue; Elastica van Gieson staining demonstrated that the former seven cases showed viable PA or a hyalinized nodule, which was old PA resulting in elastosis, in the primary tumour (Figure 2A,B) . These cases were diagnosed as CXPA of the widely invasive type. At the periphery of the old PA, atypical eosinophilic ductal cells were frequently observed as the intraductal carcinoma component or invasive SDC component ( Figure 2C,D) . In case 2 (reported previously 15 ), the primary site comprised adenocarcinoma not otherwise specified, whereas 40% of the metastatic lesion represented diffuse growth of rhabdoid cells (Figure 3A) . The invasive components, except for that in case 6, comprised diffuse proliferation of non-coherent or less coherent large ovoid atypical cells with eosinophilic cytoplasm and eccentric nuclei ( Figure 3B ). The tumour cells had marked nuclear atypia and one large nucleolus. Cytologically, such tumour cells were similar to 'rhabdoid cells'. Almost all invasive tumours showed >90% proliferation of such rhabdoid cells in invasive portions, although a few areas showed an intraductal carcinoma component or conventional SDC component at the transitional zone between the coexisting PA component and invasive lesion. One case (case 6) contained atypical cells in the luminal side of the bilayered ductal structures of the benign PA with myxochondroid stroma and spindle-shaped myoepithelial cells, and was consequently diagnosed as CXPA of the intracapsular type (Figure 3C) ; this case showed intraductal proliferation of similar less coherent ovoid atypical cells, whereas extracapsular invasion was not observed. Case 2 showed an irregularly shaped sheet-like or solid-nest growth of tightly adherent atypical polygonal tumour cells with intracytoplasmic lumens at the periphery of Figure 1 . A 'nodule-in-nodule' pattern is visible (case 1); the inner nodule shows hyaline stroma and an opaque area, whereas the invasive area shows medullary growth of cancer cells. the hyalinized nodule, but the metastatic lesions contained non-coherent ovoid cells with eosinophilic cytoplasm, eccentric nuclei, and marked cellular atypia; the metastatic lesions contained~40% rhabdoid cells. Although only a biopsy specimen was obtained in case 5, it showed proliferation of similar less coherent atypical polygonal or ovoid cells with eosinophilic cytoplasm and eccentric nuclei. As case 8 showed no evidence of pre-existing/coexisting PA, it was considered to be de-novo cancer. Case 9 showed metastatic rhabdoid cells in the cervical lymph nodes, similarly to the histological findings of the primary tumour described above. In the cervical lymph node metastases, the metastatic lesions consisted of similar rhabdoid cells, except in case 6. Although case 5 only underwent open biopsy for the primary lesion, the clinical findings indicated multiple cervical lymph node metastases.
I M M U N O H I S T O C H E M I C A L F I N D I N G S
The results of immunohistochemical staining of SDCRF cases are summarized in Table 3 . In all cases, so-called rhabdoid cells were positive for pan-CK, CK7, epithelial membrane antigen, gross cystic disease fluid protein-15 (GCDFP-15), and androgen receptor (AR), whereas all were negative for vimentin ( Figure 4 ). Seven cases were moderately to strongly positive for HER2 ( Figure 5A ), whereas only two were positive for EGFR. Only two cases were partially positive for prostate-specific antigen. Two cases were strongly positive for p53 ( Figure 5B ), whereas five were entirely negative. Two cases were weakly positive for p53. All cases showed intact nuclear positivity for SMARCB1 (INI1) ( Figure 5C ). Five cases showed loss of E-cadherin expression ( Figure 6A ), whereas three showed decreased E-cadherin expression; cytoplasmic immunolocalization was observed in these cases ( Figure 6B ). Four cases showed no bcatenin expression, whereas another four showed decreased expression ( Figure 6C) ; the latter cases showed cytoplasmic localization. However, nuclear localization of b-catenin was not observed in any case. The Ki67 labelling index was relatively high in rhabdoid cell areas of all cases, ranging from 42% to 91% (mean, 70%). Regarding mucin molecules, rhabdoid cells were positive for MUC1 and MUC6 in nine and five of nine cases, respectively. Rhabdoid cells were positive for mammaglobin in 60% of cases, whereas six of seven examinable cases showed no or decreased signals for phosphatase and tensin homologue located on chromosome 10 on immunostaining. CK14, a-smooth muscle actin, calponin, and p63, which are common myoepithelial markers, were negative in the rhabdoid cells of all cases.
F I S H A N A L Y S I S F O R H E R 2
Three cases were estimated as having a score of 2+ for HER2 immunostaining. In FISH analysis, two (cases 4 and 8) of three cases showed amplification of HER2, whereas one case (case 5) showed no amplification of HER2.
Discussion
Conventional SDC histologically mimics ductal carcinoma of the breast with high nuclear grade and a solid, cribriform or papillary type; 18 this type of carcinoma is frequently observed as a carcinomatous component of CXPA.
1-3 SDC is a high-grade malignancy in the salivary gland, and has a poor prognosis.
In 2004, Nagao et al. reported eight cases of sarcomatoid SDC, which was defined as a biphasic neoplasm. 5 In their report, only one sarcomatoid SDC showing a rhabdoid component was described, and only one figure was presented; this case showed positivity for CK and vimentin, and de-novo cancer without evidence of a PA component. We recently reported two cases of SDCRF, which were included in the present study. 16 SDCRF shows diffuse proliferation of non-coherent large ovoid atypical cells with eosinophilic cytoplasm and eccentric nuclei; this tumour is always immunopositive for SDC markers (i.e. AR and GCDFP-15). 19 Most cases of SDCRF show HER2 overexpression, like conventional SDC. Therefore, SDCRF is a new subtype of SDC. On the other hand, SDCRF frequently accompanies PA; this subtype is frequently observed as a carcinoma component of CXPA, which is also characteristic.
SDCRF is only positive for CK, and not for vimentin. 16 Although SDCRF shows the rhabdoid cell morphology, like malignant rhabdoid tumour (MRT) of the kidneys 20 or brain, 21 as well as rhabdoid-type carcinomas of other organs (i.e. the stomach, 22, 23 lungs, 24 urinary bladder, 25 and thyroid gland 26 ), the carcinoma cells of SDCRF are not 'true' rhabdoid cells, because they are not positive for both CK and vimentin. Therefore, SDCRF is not a subtype of sarcomatoid SDC.
In the present study, all cases except case 8 showed no or aberrant expression of E-cadherin and bcatenin, which are the key molecules involved in cell-cell adhesion. We have reported that down-regulation of E-cadherin is related to the morphogenesis of SDCRF. 27 The non-coherency of carcinoma cells in SDCRF could be attributable to the loss of cell-cell adhesion molecule expression. On the other hand, no cases of SDCRF showed nuclear accumulation of b-catenin. Abnormal expression of E-cadherin and b-catenin is reported to be a prognostic indicator in small-intestine adenocarcinomas, colorectal cancers, and head and neck squamous cell carcinomas. [28] [29] [30] Hereditary diffuse gastric cancer is caused by germline mutations in the E-cadherin gene (CDH1), accounting for 1% of gastric cancers, 31 whereas somatic mutation of CDH1, which is a common event in sporadic diffuse-type gastric carcinomas, has been demonstrated in~50% of diffuse gastric carcinomas but not in the intestinal type. 32 Loss of E-cadherin haemophilic cell-cell binding may result in a poorly differentiated phenotype of diffuse-type gastric carcinoma, and E-cadherin gene mutations, which affect the extracellular domain, have been observed to alter cell shape towards a less epithelioid morphology. 32, 33 Similarly, mammary lobular carcinoma is well known to not express E-cadherin. 34, 35 The results of the present study show that E-cadherin expression is reduced markedly in SDCRF. Loss of E-cadherin expression is associated with diminished cell-cell adhesion and rhabdoid morphology in SDCRF. The rhabdoid morphology of SDCRF is associated with a loss of cell-cell adhesion molecules, such as E-cadherin and b-catenin. Case 8 showed normal E-cadherin and b-catenin expression on the cellular membranes of the carcinoma cells; however, morphologically, the carcinoma cells showed less coherence. As mammary lobular carcinoma is infrequently positive for E-cadherin on cellular membranes, and some cases harbour mutation of the E-cadherin gene, 36 case 8 may have some functional mutations of E-cadherin and b-catenin genes, necessitating genetic analysis. Pleomorphic lobular carcinoma of the breast (PLCB) usually has a large plasmacytoid appearance and lacks E-cadherin expression. 37 SDCRF morphologically and immunohistochemically resembles this mammary carcinoma; of course, SDCRF is hormonally regulated by AR, unlike PLCB. 33, 34 Thus, SDCRF is considered to be the salivary counterpart of PLCB.
MRTs of the kidneys 20 or brain 21 and rhabdoidtype carcinomas are usually positive for both CK and vimentin; clinically, they are high-grade malignancies. Basaloid carcinoma with rhabdoid features in other organs, such as the sinonasal cavity 38, 39 and gastrointestinal tract, 40 were recently reported to show SMARCB1 expression deficiency. In the present study, all SDCRFs showed normal SMARCB1 expression on immunohistochemical analysis. In 2004, Fung et al. reported a case of MRT arising from PA. 41 Although their case was positive for vimentin, they did not examine the details, including immunohistochemical or genetic analysis for SMARCB1. On the other hand, Thway et al. recently reported that the rhabdoid variant of myoepithelial carcinoma of the neck harbours EWSR1 gene rearrangement. 42 They also reported that SMARCB1-deficient tumours frequently show rhabdoid features. As we confirmed the intact nuclear expression of SMARCB1 in SDCRF, we conclude that SDCRF is not a SMARCB1-deficient neoplasm.
In the present study, SDCRF was associated with poor outcomes; five patients died of the disease, whereas one patient (case 8) is alive with multiple distant metastases (i.e. bones, liver, and adrenal glands) as of the time of writing. Case 6 was intracapsular-type CXPA, and showed no invasion/ vascular permeations, which is a good outcome, similar to that of the usual intracapsular type of CXPA. In particular, case 3 had a good prognosis, but SDCRF usually results in worse outcomes than conventional SDC. As MRT and rhabdoid-type carcinomas of other organs usually have a worse prognosis, the poor outcomes of SDCRF are related to the higher invasiveness, owing to the loss of cellcell adhesion.
In summary, SDCRF is an extremely rare and SDC entity but not a histological subtype of sarcomatoid SDC. The morphogenesis of rhabdoid features in SDCRF is associated with no or aberrant expression of E-cadherin and b-catenin. SDCRF has a worse prognosis because of higher invasiveness resulting from decreased coherence of cancer cells. Owing to its less coherent large ovoid cellular morphology and lack of E-cadherin expression, SDCRF can be said to be the salivary counterpart of PLCB.
